Pediatric Acute Myeloid Leukemia Enters the Molecularly Targeted Era Via FLT3 Inhibition

Abstract

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031. March 29, 2022 ARTICLE CITATION DOI: 10.1200/JCO.22.00499 Journal of Clinical Oncology - published online before print April 18, 2022 PMID: 35436158 Pediatric Acute Myeloid Leukemia Enters the Molecularly Targeted Era Via FLT3 Inhibition Alexander E. Perl , MD1xAlexander E. PerlSearch for articles by this author Show More 1Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA https://doi.org/10.1200/JCO.22.00499 First Page Full Text PDF Figures and Tables © 2022 by American Society of Clinical OncologyAUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTPediatric Acute Myeloid Leukemia Enters the Molecularly Targeted Era Via FLT3 InhibitionThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Alexander E. PerlHonoraria: Astellas Pharma, Daiichi SankyoConsulting or Advisory Role: Astellas Pharma, Actinium Pharmaceuticals, Daiichi Sankyo, AbbVie, FORMA Therapeutics, Sumitomo Dainippon, Celgene/Bristol Myers Squibb, Syndax, Genentech, BerGenBio, ImmunogenResearch Funding: Astellas Pharma (Inst), Bayer (Inst), Daiichi Sankyo (Inst), Fujifilm (Inst), AbbVie (Inst), Syndax (Inst)No other potential conflicts of interest were reported. Companion Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031